Aside from increased levels of the HH pathway proteins in CML variants and IM-resistant samples, the study also demonstrated that these samples had upregulated BCL-2 levels and that inhibiting either SHH or BCL-2 could resensitize leukemic cells to IM [63]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.